留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

边缘区淋巴瘤的诊断与治疗进展

罗丽卿 彭振翼 王涛

罗丽卿, 彭振翼, 王涛. 边缘区淋巴瘤的诊断与治疗进展[J]. 分子影像学杂志, 2019, 42(3): 358-363. doi: 10.12122/j.issn.1674-4500.2019.03.19
引用本文: 罗丽卿, 彭振翼, 王涛. 边缘区淋巴瘤的诊断与治疗进展[J]. 分子影像学杂志, 2019, 42(3): 358-363. doi: 10.12122/j.issn.1674-4500.2019.03.19
Liqing LUO, Zhenyi PENG, Tao WANG. Diagnosis and treatment advance of marginal zone lymphoma[J]. Journal of Molecular Imaging, 2019, 42(3): 358-363. doi: 10.12122/j.issn.1674-4500.2019.03.19
Citation: Liqing LUO, Zhenyi PENG, Tao WANG. Diagnosis and treatment advance of marginal zone lymphoma[J]. Journal of Molecular Imaging, 2019, 42(3): 358-363. doi: 10.12122/j.issn.1674-4500.2019.03.19

边缘区淋巴瘤的诊断与治疗进展

doi: 10.12122/j.issn.1674-4500.2019.03.19
基金项目: 山东省自然科学基金(ZR2017PH014)
详细信息
    作者简介:

    罗丽卿,硕士,检验医师,E-mail:luoliqingwutai@163.com

    通讯作者:

    王 涛,硕士,主管技师,E-mail:wangtaoliwang@163.com

Diagnosis and treatment advance of marginal zone lymphoma

  • 摘要: 边缘区淋巴瘤是起源于边缘区记忆淋巴细胞的惰性肿瘤,属于小B细胞淋巴瘤。边缘区淋巴瘤分为脾边缘区淋巴瘤、黏膜相关淋巴组织淋巴瘤和淋巴结边缘区淋巴瘤。它们有各自不同的临床特征、形态学和病理学特征、免疫表型特征及分子遗传学特征,对其综合分析有助于各型边缘区淋巴瘤的诊断,以及与其他小B细胞淋巴瘤的鉴别诊断。近年来,随着对边缘区淋巴瘤发病机制的研究不断深入,临床治疗不断进展,许多新药物逐渐应用到临床试验中,为边缘区淋巴瘤患者的治疗提供新的希望。

     

  • [1] Swerdlow SH, Harris NL, Pileri S, et al. 造血与淋巴组织肿瘤WHO分类(第四版 上册+下册)[M].北京: 诊断病理学杂志社, 2011.
    [2] 徐 卫. 小B细胞淋巴瘤的诊断[J]. 临床内科杂志, 2015, 32(3): 163-5. doi: 10.3969/j.issn.1001-9057.2015.03.07
    [3] 楚松林, 彭敏敏, 张连生. 脾边缘带淋巴瘤诊治新进展[J]. 中华血液学杂志, 2014, 35(11): 1034-7. doi: 10.3760/cma.j.issn.0253-2727.2014.11.021
    [4] Piris MA, Onaindia A, Mollejo M. Splenic marginal zone lymphoma[J]. Best Pract Res Clin Haematol, 2017, 30(1/2): 56-64.
    [5] 孙 琦, 张培红, 刘恩彬, 等. 脾脏B细胞边缘区淋巴瘤侵犯骨髓的病理学特点与鉴别诊断[J]. 中华病理学杂志, 2013, 42(4): 234-8. doi: 10.3760/cma.j.issn.0529-5807.2013.04.005
    [6] 时云飞, 李向红. 滤泡树突细胞及Ki-67分布方式在小B细胞淋巴瘤鉴别诊断中的意义[J]. 中华病理学杂志, 2013, 42(4): 222-6. doi: 10.3760/cma.j.issn.0529-5807.2013.04.003
    [7] 李增军, 邱录贵. 边缘区淋巴瘤的多面世界和研究进展: 从2012年美国血液学会年会报道说起[J]. 白血病·淋巴瘤, 2013, 22(1): 9-10. doi: 10.3760/cma.j.issn.1009-9921.2013.01.004
    [8] Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management[J]. Blood, 2016, 127(17): 2072-81. doi: 10.1182/blood-2015-11-624312
    [9] Moody S, Escudero-Ibarz L, Wang M, et al. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma[J]. J Pathol, 2017, 243(1): 3-8. doi: 10.1002/path.2017.243.issue-1
    [10] Mendes L, Du MQ, Matutes E, et al. Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management[J]. Blood Lymphat Cancer, 2014, 4(7): 29-38.
    [11] Thieblemont C, Davi F, Noguera ME, et al. Splenic marginal zone lymphoma: current knowledge and future directions[J]. Oncology (Williston Park), 2012, 26(2): 194-202.
    [12] Lenglet J, Traullé C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment[J]. Leuk Lymphoma, 2014, 55(8): 1854-60. doi: 10.3109/10428194.2013.861067
    [13] Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma[J]. Am J Hematol, 2012, 87(11): E119-22. doi: 10.1002/ajh.v87.11
    [14] Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia[J]. Br J Haematol, 2015, 169(4): 520-7. doi: 10.1111/bjh.13320
    [15] Ayyappan S, William BM. Marginal Zone lymphoma: clinicopathologic variations and approaches to therapy[J]. Curr Oncol Rep, 2018, 20(4): 33-45. doi: 10.1007/s11912-018-0687-9
    [16] Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or withoutchemotherapy or chemotherapy alone[J]. Cancer, 2006, 107(1): 125-35. doi: 10.1002/(ISSN)1097-0142
    [17] Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma[J]. Br J Haematol, 2012, 159(3): 322-8. doi: 10.1111/bjh.12036
    [18] Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy[J]. Oncologist, 2013, 18(2): 190-7. doi: 10.1634/theoncologist.2012-0251
    [19] Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma[J]. Ann Hematol, 2014, 93(3): 449-58. doi: 10.1007/s00277-013-1900-4
    [20] Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma[J]. Hematol Oncol, 2007, 25(3): 127-31.
    [21] Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of Lymphoma (CISL) study[J]. Ann Hematol, 2012, 91(4): 543-51. doi: 10.1007/s00277-011-1337-6
    [22] Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas[J]. Br J Haematol, 2009, 145(6): 741-8. doi: 10.1111/bjh.2009.145.issue-6
    [23] Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation[J]. Cancer, 2012, 118(16): 3954-61. doi: 10.1002/cncr.26708
    [24] Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of Mucosa-Associated lymphoid tissue lymphoma: improved Event-Free and Progression-Free survival with rituximab plus chlorambucil versus either chlorambucil or RituximabMonotherapy[J]. J Clin Oncol, 2017, 35(17): 1905-12. doi: 10.1200/JCO.2016.70.6994
    [25] Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial[J]. Lancet, 2013, 381(9873): 1203-10. doi: 10.1016/S0140-6736(12)61763-2
    [26] Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study[J]. Blood, 2014, 123(19): 2944-52. doi: 10.1182/blood-2013-11-531327
    [27] Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of the multicenter phase IItrial with Bendamustine and rituximab as first line treatment for patients with maltlymphoma (MALT-2008-01)[J]. Hematol Oncol, 2017, 35(S2): 147-8.
    [28] Vannata B, Stathis A, Zucca E. Management of the marginal zone lymphomas[J]. Cancer Treat Res, 2015, 165: 227-49. doi: 10.1007/978-3-319-13150-4
    [29] Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II Anti-CD20 monoclonal antibody, for the treatment of patients with B-Cell malignancies[J]. Adv Ther, 2017, 34(2): 324-56. doi: 10.1007/s12325-016-0451-1
    [30] Noy A, de Vos S, Thieblemont C, et al. Targeting bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma[J]. Blood, 2017, 129(16): 2224-32. doi: 10.1182/blood-2016-10-747345
    [31] Conconi A, Martinelli G, Lopez-Guillermo A, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)[J]. Ann Oncol, 2011, 22(3): 689-95. doi: 10.1093/annonc/mdq416
    [32] Kiesewetter B, Willenbacher E, Willenbacher W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma[J]. Blood, 2017, 129(3): 383-5. doi: 10.1182/blood-2016-06-720599
    [33] Nastoupil L, Lunning MA, Vose JM, et al. Chemo-free triplet combination of TGR-1202, Ublituximab, and Ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL[J]. Hematol Oncol, 2017, 102(2): 312-23.
    [34] Nakamura S, Sugiyama T, Matsumoto TA, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan[J]. Gut, 2012, 61(4): 507-13. doi: 10.1136/gutjnl-2011-300495
    [35] Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21)in Helicobacterpylori-negative gastric MALT lymphoma[J]. Blood, 2003, 101(7): 2547-50. doi: 10.1182/blood-2002-10-3167
    [36] Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy[J]. Lancet, 2001, 357(9249): 39-40. doi: 10.1016/S0140-6736(00)03571-6
    [37] Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication[J]. J Clin Oncol, 2005, 23(31): 8018-24. doi: 10.1200/JCO.2005.02.3903
    [38] Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas[J]. Hematol Oncol, 2005, 23(1): 10-7.
    [39] 王建祥. 血液病诊疗规范[M]. 北京: 中国协和医科大学出版社, 2014.
    [40] Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2015, 92(1): 11-31. doi: 10.1016/j.ijrobp.2015.01.009
    [41] Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as First-Line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial[J]. J Clin Oncol, 2012, 30(24): 2988-94. doi: 10.1200/JCO.2011.41.4466
    [42] Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma[J]. Blood, 2016, 127(17): 2064-71. doi: 10.1182/blood-2015-12-624296
    [43] Makarova O, Oschlies I, Müller S, et al. Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma[J]. Br J Haematol, 2018, 182(5): 735-9. doi: 10.1111/bjh.14868
  • 加载中
计量
  • 文章访问数:  1412
  • HTML全文浏览量:  382
  • PDF下载量:  40
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-05-15
  • 刊出日期:  2019-07-01

目录

    /

    返回文章
    返回

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者:

    为了缩短出版时滞,促进科研成果的快速传播,我刊自2024年1月起,刊期由双月刊变更为月刊。本刊主要栏目有:基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱!

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日